J Korean Med Sci.  2014 Nov;29(11):1550-1554. 10.3346/jkms.2014.29.11.1550.

Efficacy and Tolerability of Anticholinergics in Korean Children with Overactive Bladder: A Multicenter Retrospective Study

• Park SJ
• Pai KS
• Kim JM
• Park K
• Kim KS
• Song SH
• Park S
• Kim SO
• Ryu DS
• Baek M
• Lee SD
• Lee JW
• Im YJ
• Han SW
• Chung JM
• Cho MH
• Ha TS
• Cho WY
• Suh HJ
• The Korean Children's Continence and Enuresis Society

• KMID: 2069938
• DOI: http://doi.org/10.3346/jkms.2014.29.11.1550

Abstract

We investigated the efficacy and tolerability of various anticholinergics in Korean children with non-neurogenic overactive bladder (OAB). A total of 326 children (males:females= 157:169) aged under 18 yr (mean age 7.3+/-2.6 yr) who were diagnosed with OAB from 2008 to 2011 were retrospectively reviewed. The mean duration of OAB symptoms before anticholinergic treatment was 16.9+/-19.0 months. The mean duration of medication was 5.6+/-7.3 months. Urgency urinary incontinence episodes per week decreased from 1.9+/-3.1 to 0.4+/-1.5 times (P<0.001). The median voiding frequency during daytime was decreased from 9.2+/-5.4 to 6.3+/-4.2 times (P<0.001). According to 3-day voiding diaries, the maximum and average bladder capacity were increased from 145.5+/-66.9 to 196.8+/-80.3 mL and from 80.8+/-39.6 to 121.8+/-56.5 mL, respectively (P<0.001). On uroflowmetry, maximum flow rate was increased from 17.6+/-8.4 to 20.5+/-8.2 mL/sec (P<0.001). Adverse effects were reported in 14 (4.3%) children and six children (1.8%) discontinued medication due to adverse effects. Our results indicate that anticholinergics are effective to improve OAB symptoms and tolerability was acceptable without severe complications in children.

Keyword

Overactive Urinary Bladder; Urinary Incontinence; Anticholinergics; Efficacy; Tolerability

MeSH Terms

Child
Child, Preschool
Cholinergic Antagonists/adverse effects/*therapeutic use
Constipation/etiology
Dizziness/etiology
Female
Humans
Male
Retrospective Studies
Treatment Outcome
Urinary Bladder, Overactive/*drug therapy
Cholinergic Antagonists

Reference

1. Sureshkumar P, Craig JC, Roy LP, Knight JF. Daytime urinary incontinence in primary school children: a population-based survey. J Pediatr. 2000; 137:814–818.

2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21:167–178.

3. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, de Ridder D, Dmochowski R, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010; 29:213–240.

4. Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W, Jørgensen TM, Rittig S, Walle JV, Yeung CK, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol. 2006; 176:314–324.

5. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 2006; 60:119–126.

6. MacDiarmid SA. How to choose the initial drug treatment for overactive bladder. Curr Urol Rep. 2007; 8:364–369.

7. Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol. 2008; 4:428–433.

8. Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, et al. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. BJU Int. 2010; 106:550–556.

9. Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010; 184:1668–1673.

10. Schröder A, Thüroff JW. New strategies for medical management of overactive bladder in children. Curr Opin Urol. 2010; 20:313–317.

11. Nørgaard JP, van Gool JD, Hjälmås K, Djurhuus JC, Hellström AL. Standardization and definitions in lower urinary tract dysfunction in children. International Children's Continence Society. Br J Urol. 1998; 81:1–16.

12. Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010; 106:506–514.

13. Chung JM, Lee SD, Kang DI, Kwon DD, Kim KS, Kim SY, Kim HG, Moon du G, Park KH, Park YH, et al. Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study. Urology. 2009; 73:63–67. discussion 68-9.

14. MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int. 2007; 99:8–12.

15. Kim WJ, Lee DG, Lee SW, Lee YK, Lee JS, Park KH, Baek M. Efficacy and safety of propiverine in children with overactive bladder. Korean J Urol. 2012; 53:275–279.

16. Kim SO, Kim KD, Kim YS, Kim JM, Moon du G, Park S, Lee SD, Chung JM, Cho WY. Korean Children's Continence and Enuresis Society. Evaluation of maximum voided volume in Korean children by use of a 48-h frequency volume chart. BJU Int. 2012; 110:597–600.

17. Wada Y, Yoshida M, Kitani K, Kikukawa H, Ichinose A, Takahashi W, Gotoh S, Inadome A, Machida J, Ueda S. Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther. 1995; 330:76–89.